Mealey to launch three new monthly reports this summer.
With a premier issue in July, Mealey's Intellectual Property Pleadings is designed to present intellectual property law "from the perspective of the voices of those involved in patent, trademark and copyright battles," Mealey said. To be published twice a month, the report will carry a range of fillings from ongoing intellectual property cases, including pleadings, documents and summaries. Available in print or online, an annual subscription costs $699. Mealey also publishes the Intellectual Property, Patents, Trademarks, Cyber Tech & E-Commerce and Copyright litigation reports.
Mealey's Litigation Report: Hormone Replacement Therapy is a new monthly report designed to help attorneys keep track of the hundreds of law suits involving cases of the use of the hormone replacement therapy (HRT) drugs Premarin, Prempro, Premelle, Progestin and related HRT drugs. Content in the report will include case news, filings, opinions and pleadings, legislative news and FDA reports.
The first issue will include coverage of: a national class action filed in federal court in May against three pharmaceutical companies alleging that the use of HRT caused death and injuries; a request to the Prempro MDL court by Wyeth to create a Defendants' Steering Committee to include counsel representing other manufacturers and physician defendants; and, the results of a Canadian health task force on the use of HRTs. Also available in print or online, an annual subscription costs $599.
To help plaintiff and defense counsel track the growing area of litigation involving the use of selective serotonin reuptake inhibitors (SSRIs), a class of prescribed antidepressant drugs, Mealey will launch Mealey's Litigation Report: Antidepressant Drugs. The monthly will cover litigation covering the drugs Paxil, Prozac, Effexor, Zoloft, Celexa, Luvox, Wellbutrin, Serzone, Remeron and Lexapro.
Initial issues will include coverage of such topics as: a New York State lawsuit alleging that GlaxoSmithKline concealed efficacy and safety issues; a ruling that there is a material question of fact about the adequacy of a warning about Serzone; a Canadian health advisory on the use of SSRIs; and, an admission that an FDA staff doctor was not allowed to present his conclusion that there is an association between SSRIs and suicide in children to an advisory committee. Also available online or inprint, an annual subscription costs $599.
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 1, 2004|
|Previous Article:||Workplace Injury Litigation.|
|Next Article:||ALM launches "GC California," "GC New York" & new conference.|